Biotech firm Candel Therapeutics reels in $22.5 mln Series C

Candel Therapeutics, a biotech firm, has raised $22.5 million in Series C financing. Northpond Ventures led the round. In addition to the funding, Dr. Michael P. Rubin, founder and CEO of Northpond Ventures, will join Candel Therapeutics’ board of directors.

Source: Press Release